missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ FLT3LG Monoclonal Antibody (D13)

Mouse Monoclonal Antibody
Brand: Invitrogen™ MA541588
This item is not returnable.
View return policy
Description
FLT3LG Monoclonal Antibody for Western Blot
FLT3LG (Fms Related Tyrosine Kinase 3 Ligand) is a Protein Coding gene. Diseases associated with FLT3LG include Aplastic Anemia and Brain Cancer. Among its related pathways are Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers and Ras signaling pathway. Gene Ontology (GO) annotations related to this gene include protein homodimerization activity and cytokine activity. Dendritic cells (DCs) provide the key link between innate and adaptive immunity by recognizing pathogens and priming pathogen-specific immune responses. FLT3LG controls the development of DCs and is particularly important for plasmacytoid DCs and CD8-positive classical DCs and their CD103-positive tissue counterparts.
Specifications
| FLT3LG | |
| Monoclonal | |
| 1 mg/mL | |
| PBS with 50% glycerol and 0.05% ProClin 300; pH 7.4 | |
| P49771 | |
| FLT3LG | |
| Recombinant protein FMS Like Tyrosine Kinase 3 Ligand. The antigen corresponds to amino acid range 83-182 of the target protein. | |
| 200 μL | |
| Primary | |
| Human | |
| Antibody | |
| IgG2a κ |
| Western Blot | |
| D13 | |
| Unconjugated | |
| FLT3LG | |
| FL; Flt 3 ligand; Flt3; Flt3 L; Flt3 ligand; Flt3l; Flt3lg; fms related receptor tyrosine kinase 3 ligand; fms related tyrosine kinase 3 ligand; FMS-like tyrosine kinase 3 ligand; fms-related tyrosine kinase 3; fms-related tyrosine kinase 3 ligand; H-FLT-3-L; Ly72L; M-FLT-3-L; NEWGENE_2322792; SL cytokine | |
| Mouse | |
| Protein A/G | |
| RUO | |
| 2323 | |
| Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
| Liquid |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction